Efficacy and Safety of Intermittent Versus Continuous Dose Apatinib Plus Docetaxel As Second-Line Therapy in Patients with Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma: a Randomized Controlled Study.

Annals of translational medicine(2022)

引用 3|浏览23
暂无评分
关键词
Apatinib,docetaxel,intermittent dose,continuous dose,gastric cancer or gastroesophageal junction adenocarcinoma (GC/GEJAC)
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要